Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
latest_posts
- 1
CRP Subsea secures contract for Vattenfall’s Nordlicht I cable systems - 23 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- 3Figure out How to Acquire Rewarding Open Record Rewards
- 4Russian military plane crashes in annexed Crimea, killing 29 people on board
- 5IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- Audits of 6 American Busssiness Class Flights
- Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026
- A somber Thor is returning for 'Avengers: Doomsday': Watch the dread-filled teaser
- Insane Realities That Will Make You Reconsider How you might interpret History
- Manual for Wonderful Getaway destination
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
- Bond Girl Ursula Andress’ $23 Million Fortune Once ‘Fraudulently Misappropriated’ Was Allegedly Found
- They want better health care — so they're turning to crypto startups
- How a rare drug made from scientists' blood saves babies from botulism
